After the closing bell today, Dominovas Energy issued a press release that emphasizes and details the scope of the Power Africa Initiative announced earlier this week. Specifically, Dominovas Energy Corporation has been named as the first, and only, fuel cell company selected as a Private Sector Partner to President Barack Obama’s POWER AFRICA INITIATIVE. The Power Africa Initiative (PAI) is a multi-stakeholder partnership comprised of over 100 private sector partners. However, the Power Africa Initiative scope is, in fact, more expansive than the initial six countries previously reported. Power Africa is designed to provide support for all countries in sub-Saharan Africa, but in the first year offered intensive regulatory reform support and technical assistance to an initial set of six Power Africa focus countries – Ethiopia, Ghana, Kenya, Liberia, Nigeria, and Tanzania. These countries signed Memoranda of Understandings with Power Africa, which reflect the strong commitment of African governments to engage in policy and regulatory reform, and in particular to implement critical energy sector reforms. Through PAI, public sector agencies / entities maintain an express intent to nurture and accelerate private sector investment in sub-Saharan Africa’s power sector over the next several years.

Power Africa private sector partners represent the foundational support in building the regulatory, economic, and policy framework integral to meeting sub-Saharan Africa’s increasing demand for, and access to, electricity; and Dominovas Energy anticipates this partnership will continue to catalyze the resources and combined commitment of numerous U.S. government agencies, as well as the World Bank Group, AfDB, and many additional Power Africa partners, to facilitate Power Africa’s objectives, operations, and related sector investments. Detailed earlier this week, as a Power Africa private sector partner, Dominovas Energy will actively engage relevant U.S. agencies to fully employ the participating agencies’ tools to ensure any financing and capacity gaps that may exist can be addressed directly, specifically with respect to existing and incremental energy sector investments. These resources will allow Dominovas Energy to benefit from interagency efforts, by leveraging Power Africa’s tools including, but not limited to technical expertise and financing; while enhancing project bankability by implementing various risk mitigation tools.

Dominovas Energy’s President of its Africa Division, Emilio De Jesus, added, “With Power Africa’s commitment to the entire sub-Saharan Africa, it has set the stage for Dominovas Energy to complete sales cycles it began in earnest over two years ago with government officials of respective nations working closely with our company to realize a viable solution to their energy sector concerns.”

Over the next several years, as part of its commitment to Power Africa, Dominovas Energy intends to support and advance Power Africa goals by providing access to clean, reliable energy; partnering with specific universities in sub-Saharan Africa to train and hire local citizens as engineers and technicians, as necessary for the installation, service, and ongoing maintenance of the RUBICON™; and providing sub-Saharan countries with access to distributed, off-grid electricity on a multi-megawatt scale.

For more information on Dominovas Energy and its fuel cell technology, visit www.dominovasenergy.com

Let us hear your thoughts: Dominovas Energy Corp. Message Boards

Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s leading product candidate, omadacycline, is the first in a new class of antibiotics derived from tetracyclines for use as a first-line monotherapy to treat serious bacterial infections when antibiotic resistance is a cause of concern.

In recent weeks, Paratek has continued to progress with the development of omadacycline. Earlier this month, the company initiated a phase III clinical trial of the drug candidate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). This study is meant to assess the efficacy and safety of omadacycline in treating ABSSSI, particularly as compared with current treatment option linezolid. The company’s second phase III trial on the drug candidate, which will begin enrolling patients later this year, will study its effectiveness in treating community-acquired bacterial pneumonia (CABP).

“The initiation of our registration trial for ABSSSI represents an important milestone for Paratek as a company,” Michael Bigham, chairman and chief executive officer of Paratek, stated in a news release. “We believe that omadacycline has the potential to become an important empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, urinary tract infections and other bacterial infections when resistance is of concern.”

Upon commercialization, the potential market for Paratek’s novel antibiotic treatment is immense. According to a 2013 report by the Centers for Disease Control and Prevention, at least two million people in the United States become infected with bacteria that are resistant to conventional antibiotic treatment options each year, and an estimated 23,000 people die as a result of these infections.

In the first quarter of 2015, Paratek positioned itself to move forward with its omadacycline trials by securing approximately $71 million in funding through a common stock offering. With financing complete, the company will look to accelerate its existing clinical development plans, as well as adding a third potential indication in urinary tract infections (UTI), in the months to come. Based on current assumptions, Paratek’s cash and cash equivalents are expected to fund operations through mid-2017, which is expected to coincide with the availability of top-line data from the company’s CABP trial.

For prospective shareholders, the vast market potential of omadacycline and the current financial standing of Paratek combine to make the company an intriguing investment opportunity moving forward. As Paratek continues to make strides toward the commercialization of its innovative drug candidate, look for the company to clear the path for sustainable returns in the years to come.

For more information, visit www.paratekpharm.com

The state of Nevada is in high anticipation about its upcoming 2016 general election ballot initiative that proposes legalizing recreational use of marijuana. With Colorado’s $700 million wind-fall last year and trending to break $1 billion in annual revenues by 2016, the MMJ market in Nevada could very quickly get a whole lot bigger next year.

Poised and positioned to capitalize on this upcoming opportunity is GrowBLOX Sciences. The company has advanced cultivation technology systems that ensure genetic potential of propagated strains that possess more active ingredients per pound than is achieved with any other cultivation method. On June 15th, the company secured a $1.75 million funding commitment from Pacific Leaf Ventures to build out its Medical Marijuana Establishment known as The Cultivation Lab through a deal that includes recognizable cannabis brand names and proprietary cultivation and extraction methods. The 28,000 sq. ft. warehouse is gearing up to produce over 4000 pounds of high-grade cannabis each year.

Although GrowBLOX Sciences deals strictly in medical cannabis products, the monitoring and control systems that are put in place to ensure quality and safety standards at the Las Vegas facility is quickly drawing attention and could possibly be the mandated standard in Nevada by the time legalization is put in place. See The Cultivation Lab design at the following link: http://www.cultivationlabs.com.

GBLX is on schedule for a Q4 completion of The Cultivation Lab. This facility’s purpose is to produce high profile strains and products that appeal to medically approved patients in the state, as well as patients visiting from neighboring Arizona and California. Nevada is the only state to date that recognizes medical marijuana patient cards issued by other states.

The GBLX product line will be distributed from The Apothecary, an eye catching retail space that combines the trustworthy aesthetics of a clean, minimalistic and clinical-feeling interior, with simplified biometrically driven patient verification. The Apothecary layout has a security foyer for initial patient processing, waiting and consultation rooms as well as retail display area, and secure payment section. See the Las Vegas Apothecary at the following link: https://vimeo.com/129493221.

The company believes that combining The Cultivation Labs and The Apothecary will offer patients the quality assurance and safety that they have a grown to expect from any other therapeutic products purchased in the open market. These big moves in Nevada should distinguish GrowBLOX Sciences further from the other players in the field and help make GBLX a preferred solution provider.

For more information, visit www.gbsciences.com

Let us hear your thoughts: GrowBLOX Sciences, Inc. Message Board

IGEN Networks Corp. (OTCQB: IGEN) invests in and manages businesses that deliver cloud-based services through machine-to-machine (M2M) device technologies for the protection and management of mobile assets and commercial fleets. By taking an active managerial role in these businesses, IGEN allows its technology subsidiaries to mitigate operational risk and realize revenue growth and capital appreciation. In addition to providing management expertise, IGEN utilizes an established network of distribution channels to efficiently negotiate distribution agreements and sell a wide range of products and services.

In recent months, IGEN has leveraged this strategy to great success. In May, the company, through wholly-owned subsidiary Nimbo LLC, signed a major account agreement with Verizon Wireless (NYSE: VZ). Through this agreement, Nimbo will become a member of Verizon’s partner program for the marketing of Nimbo’s M2M and integrated GPS tracking solutions over the mobile giant’s national wireless services. The company will also gain access to Verizon’s established database of sales leads, which encompasses major automotive dealer markets across the United States.

“This partnership program with Verizon Wireless is significant for us,” Neil Chan, chief executive officer of IGEN, stated in a news release. “It enables our sales team to partner with Verizon, the largest wireless operator in the U.S., to sell into automotive dealer channels and reach large new potential customers.”

Earlier this month, the company, through Nimbo, built upon this progress through the announcement of a partnership with Star Shield Solutions LLC and Sky Force Technology, Inc. to launch a pilot program targeted at a high volume automotive dealership store in southern California.

By consistently targeting nationwide dealer channels, IGEN is tapping into a potentially massive source of future revenue. According to First Research, dealer channels accounted for over $700 billion in annual revenue through the sale of 15.6 million new vehicles and 40.5 million used vehicles throughout the U.S. in 2013. By 2018, these figures are expected to double, creating an expansive market for the company’s mobile asset protection services.

In the first quarter of 2015, IGEN recorded a 756 percent year-over-year increase in revenue to go alongside gross profit figures that were consistent with the fourth quarter of 2014. As the company continues to work toward stabilizing its inventory position and product costs, recent results could foreshadow continued market growth moving forward.

For more information, visit www.igen-networks.com

Cytori Therapeutics, Inc. is a biotechnology company developing autologous cell therapies from adipose connective tissue designed to treat a variety of medical conditions. Since 2001, the company has leveraged its exploration of the massive treatment potential of adult adipose-derived stem and regenerative cells to position itself as a global leader in the emerging field of regenerative medicine. By utilizing a patient’s own adipose tissue, Cytori eliminates the necessity for offsite cell growth operations while effectively minimizing common transplant risks, including autoimmune rejection.

The company’s current cell therapy pipeline includes three drug candidates in six unique indications across two countries and the European Union. Cytori’s leading candidate, ECCS-50, is currently approved in the United States and Europe to begin a phase III clinical trial for the treatment of scleroderma hand dysfunction.

According to the National Institute of Health, scleroderma is a group of diseases that affect connective tissue in the body, potentially causing swelling or pain in the muscles and joints. Despite affecting as many as 100,000 people in the United States, there is currently no drug that has been clearly proven to stop, or reverse, the disease’s key symptoms. For Cytori, this unmet need should clear the way for favorable results upon the eventual commercialization of ECCS-50.

From a financial standpoint, Cytori took major steps in the first quarter of 2015 toward continued development and testing of its promising product pipeline. The company’s operating cash burn was reduced by over 44 percent in the period and overall contract revenue rose by 350 percent, as compared to the first quarter of 2014, providing prospective investors with a preview of the Cytori’s growth potential moving forward.

“We accomplished the key objectives we hoped to achieve over the past four quarters and are off to a good start in 2015,” Dr. Marc H. Hendrick, president and chief executive officer of Cytori, stated in a news release. “Now the lion’s share of our corporate focus and energy will go into trial enrollment and strategically managing our clinical pipeline.”

In June, the company made progress toward this objective through the completion of enrollment for its impending phase IIb clinical trial, which will study the safety, feasibility and dosing intraarticular administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee osteoarthritis. Look for the company to build on this progress in the months to come as it prepares for its pivotal phase III trial of ECCS-50.

For more information, visit www.cytori.com

Galaxy Gaming, Inc. (OTCQB: GLXZ) is a gaming company that’s engaged in the business of designing, manufacturing and acquiring proprietary casino table games and associated technology, platforms and systems for the global gaming industry. The company’s current base of products includes over 4,000 gaming tables located in more than 500 casinos, making it the world’s largest independent provider of proprietary table games.

Leveraging a formidable portfolio of intellectual property related to its unique game concepts, Galaxy markets its products to land-based, riverboat and cruise ship gaming establishments, as well as internet gaming companies, in order to enhance their gaming floor operations and improve profitability, productivity and security.

In the first quarter of 2015, Galaxy achieved a 14 percent year-over-year increase in total revenue, recording more than $2.5 million for the period. Despite a 15 percent year-over-year decrease in adjusted EBITDA for the quarter, Galaxy’s management team is optimistic about the strength of the company’s market position moving forward.

“The first quarter has historically been the period we see the lowest revenue growth rates of the year,” Gary A. Vecchiarelli, chief financial officer of Galaxy, stated in a news release. “While several factors contributed to our first decrease of recurring revenues in the last three years, we are not concerned it will have impact on future quarters. Our adjusted EBIDTA and fundamentals of the business remain strong and we expect a strong 2015.”

In April, Galaxy took a significant step toward continued growth when it achieved approval from the Kansas Racing and Gaming Commission to conduct business directly with state-owned casinos. This should provide the company with a platform for considerable industry growth in the months to come. According to a report by the Kansas Lottery, Kansas’s three state-owned casinos are expected to account for more than $336 million in gaming revenue during 2015.

“This approval now opens the door for us to conduct business directly with Kansas casino operators,” stated Robert Saucier, chief executive officer of Galaxy. “We now intend to aggressively increase our presence there and expand our already established great partnerships with many of the prosperous casino resorts located in that market.”

Under the leadership of a proven management team, Galaxy is in a strong position to increase its industry presence within the thriving casino industry in the years to come. According to a report by Statista, global casino gaming revenue has experienced consistent growth since 2009, climbing to forecast revenue of more than $182 billion in 2015. For prospective investors, Galaxy’s strategic position within one of the most consistently performing sectors of the global economy could translate into sustainable returns moving forward.

For more information, visit www.galaxygaming.com

Organovo Holdings, Inc. (NYSE MKT: ONVO) is an early commercial stage company focusing on the development and commercialization of functional human tissues for use in drug discovery and medical research. Utilizing its proprietary three-dimensional bioprinting technology, the company enables reproducible, automated creation of living human tissues that mimic the form and function of native tissues in the body. Organovo’s exVive3D™ product portfolio includes a recently launched 3D human liver tissue for use in toxicology and preclinical drug testing. The company plans to expand upon its existing product portfolio in the latter half of 2016 through the launch of its exVive3D human kidney tissue.

Since launching its 3D human liver tissue on April 1, 2014, the company has made significant strides toward increasing its market share within the $50 billion research and development sector of the pharmaceutical industry. Earlier this month, Organovo reported that it had already recording total contract bookings for its innovative product amounting to approximately $1.94 million, including $0.29 million in existing revenue. Among these orders, the company secured partnerships with top 25 global pharmaceutical companies, as well as additional public pharmaceutical companies of all sizes in the United States, Europe and Asia.

“Response to the exVive3D human liver tissue has been strong, and in line with our expectations,” Keith Murphy, chief executive officer of Organovo, stated in a news release. “We continue to expect this tissue to grow into the tens of millions in annual revenue, and that it has $100M+ revenue potential.”

For Organovo, fiscal year 2015 was filled with milestones that should provide the company with a strong platform to realize sustainable returns moving forward. The release of the exVive3D human liver tissue set the stage for a host of industry recognition – including being named among the ‘Top 10 Innovations of 2014’ by The Scientist magazine and ‘The World’s Top 10 Most Innovative Companies of 2015’ by Fast Company magazine. Additionally, Organovo diversified its market potential through a partnership with L’Oreal USA to develop 3D printed skin tissues for product evaluation, marking the company’s first foray into the beauty industry.

The company’s current momentum following the successful release of its initial product could be a promising indication of Organovo’s future growth potential. For prospective shareholders, the recent commercialization of its exVive3D human liver tissue, as well as the continued development of its human kidney tissue product, makes Organovo an exciting investment opportunity to put on radar.

For more information, visit www.organovo.com

Cleartronic is wrapping up the first half of 2015 with a flurry of activity. Earlier this month the company’s ReadyOp Communications subsidiary launched a project with a major retail corporation, and followed-up the news that its VoiceInterop, Inc. subsidiary had signed a deal with an airport in Alberta, Canada.

As a technology holding company, Cleartronic is amassing a portfolio of subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises. Cleartronic is carving its niche in a broader industry occupied by wireless communications companies like Fusion Telecommunications International, Inc. (NASDAQ:FSNN) and Ubiquiti Networks, Inc. (NASDAQ:UBNT), differentiating itself by offering unique interoperable communications solutions.

Through a license agreement with Collabria LLC, Cleartronic has the right to market the command, control and communication platform, ReadyOp™. The web-based application integrates multiple databases and a robust communications platform to enable fast, efficient access to information and for communication with multiple persons, groups and agencies.

While ReadyOp is typically used by numerous federal, state and local government agencies, Cleartronic is expanding its applications to a variety of industries. ReadyOp Communications recently began work on a multi-year with a major retail corporation based in Arkansas. The project will integrate the ReadyOp platform for the planning, monitoring and reporting of the work done for each individual store location.

“We are pleased to be an integral part of this project as it shows the versatility and flexibility of the ReadyOp platform. While our main focus has been with first responders and government agencies, this project illustrates how ReadyOp can be used in many different industries. This will be our first entry into the retail sector and our plans are to use this project as a model for other opportunities in the retail sector,” ReadyOp Communications President Marc Moore stated in the news release.

Effective communication is a benchmark of Cleartronic’s operations, and to that accord, VoiceInterop recently signed an agreement with the Edmonton Airports in Alberta, Canada, to provide mission critical system for emergency response at Edmonton International Airport.

VoiceInterop’s emergency communication solution, the “VoiceInterop Crash Phone,” combines VoiceInterop’s engineered software with modern, commercial off-the-shelf products that specifically address the needs of commercial aviation airports. Per the agreement, VoiceInterop has engineered and will install, test and provide support for a customized state-of-the-art crash phone solution – the most vital piece of an airport’s communications system – that provides instant voice communications from the air traffic control tower to the airport rescue firefighting station, communications center, and airport police.

For more information, visit www.cleartronic.com

Let us hear your thoughts: Cleartronic, Inc. Message Board

Governments and insurance companies around the world are seeking innovative technologies that address the needs of the growing diabetic population in over-burdened public and private healthcare systems. In the U.S. alone, the national cost of diabetes in 2012 was $245 billion, compared to $174 billion in 2007.

LabStyle Innovations (OTCQB:DRIO) is answering this call with a preventative approach that reduces the cost of care while improving treatment and patient compliance. The company’s Dario™ Diabetes Management Solution is designed to help people with diabetes manage their disease with tools, insights and support via mobile phone.

The Dario™ all-in-one glucose monitoring solution includes a glucose meter, disposable test strip cartridge, and lancing device – all in a compact design that can fit into a pocket. The meter plugs into a smartphone device to automatically log and track blood sugar levels to provide actionable insights and alerts. Data is uploaded into a secure cloud database for diabetes-related clinical trials.

The platform’s web interface simplifies data sharing and progress, enabling easy and effective data management and ensuring patient compliance and improved quality of care. The Caregiver portal is being developed in order to assist caregivers to monitor their patients quickly and easily as well as enable more effective intervention as necessary – ultimately reducing costs.

Bottom line, Dario offers a preventative approach that reduces the costs of care, improves treatment, helps to prevent complications and facilitates patient compliance.

In April, LabStyle announced the initial stages of its global rollout of the Dario Diabetes Management System. The company’s goal is to “transform the daily management of diabetes” targeting the world’s more than 382 million people living with diabetes – a statistic expected to nearly double to 592 million by 2035.

Dario has already received regulatory approval in Europe, and U.S. FDA approval is expected later this year. The U.S. Patent and Trademark Office granted LabStyle a patent covering core functions of the Dario, and the company is pursuing patent applications in additional countries. Dario is currently available in the United Kingdom, New Zealand, Netherlands and Australia, and LabStyle plans to launch the solution in Canada and Italy this year as well.

The Israel-based company participates alongside bigger players addressing the global diabetes care market, including DexCom, Inc. (NASDAQ:DXCM), which develops and markets glucose monitoring products for adults and pediatric patients. Even Apple, Inc. (NASDAQ:AAPL) has jumped into the glucose monitoring market with an Apple Watch app developed by DexCom.

In terms of sales, the diabetes market is dominated by drug makers Novo Nordisk (NYSE:NVO), Sanofi (NYSE:SNY), and Merck (NYSE:MRK), in that order, according to data analytics firm GlobalData. The same report shows the Top 10 diabetes drugmakers, which also includes Pfizer (NYSE:PFE) and Eli Lilly (NYSE:LLY), made $62 billion in combined global sales last year, up more than 5 percent from the year prior.

If the crowded market and increasing number of diabetics worldwide is any inclination, LabStyle is in an opportunistic position to take its share of a rapidly growing market in need of innovative, cost-saving technologies and solutions.

For more information, visit www.mydario.com

Today, Galenfeha announced on its website that the company has brought on Chris W. Watkins as Senior Business Development Manager in its sales department. He joined Galenfeha on June 15, 2015.

Mr. Watkins adds nearly three decades of sales and management experience in the oil and gas industry, including directing sales operations and managing distributors throughout the Midwest and Rocky Mountain regions. Most recently, Mr. Watkins served as an Asia/Asia Pacific sales director, responsible for establishing international distribution channels, training distributors, and promoting product lines.

This news closely follows Galenfeha’s recent agreement with BHP Billiton (NYSE: BHP), in which Galenfeha will provide the U.S. oil and gas producer with advanced stored energy solutions. The move immediately broadens Galenfeha’s penetration in the oil and gas industry, and supports the company’s efforts to rapidly become a premier alternative stored energy supplier in North America, where it can further leverage its line of patent pending, microprocessor controlled, LiFePO4 chemistry battery systems for measurement, automation, and a full line of proprietary chemical injection systems.

For more information, visit www.galenfeha.com

Let us hear your thoughts: Galenfeha, Inc. Message Board